NLSP News

NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, raised $20 million by offering 4.8 million units at $4.15, below the range of $5 to $6. The company offered 1.2 million more units than anticipated. Each unit consists of one share of common stock and one warrant, exercisable at $4.15. ...read more

NLS Pharmaceutics, which is developing controlled-release formulations of approved drugs for ADHD and narcolepsy, announced terms for its IPO on Monday. The Stans, Switzerland-based company plans to raise $20 million by offering 3.6 million units at a price range of $5 to $6. Each unit consists of one share of common stock and one warrant, which will be exercisable at a price...read more

There are no IPOs scheduled for the week ahead. The most likely April IPOs Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed, indicating the IPO market’s slow April will continue. April’s headline IPO could come from grocery giant...read more

Following the IPO Index’s sharpest drop ever recorded, one cannabis SPAC is keeping the IPO market alive, expected to raise $150 million in the week ahead. Social Capital’s latest SPACs (IPOB.U, IPOC.U) are also eligible to price this week. Led by former Canopy Growth executives, Collective Growth Corp (CGROU) plans to raise $150 million at a...read more